Thursday, November 19, 2026

US Treasury Department’s Proposed China Crackdown on American investments in chinese companies Could Backfire on American Patients

Concerning! This could indeed be a double edged sword!

However, the final rules may not be issued much earlier than before the deadline of 3/13/2027. The devil will be in the details. Perhaps, it will not turn out as bad as these news suggest.

"Several of the most exciting breakthroughs in cancer care are coming from China. New rules proposed by the Trump administration could make it harder for American patients to access those medicines.

On October 22, the Treasury Department proposed expanding restrictions on American investment in Chinese companies to include biotechnology. The proposal aims to prevent American capital and expertise from helping China develop technologies that could threaten U.S. national security.

That’s a legitimate concern. But there’s a world of difference between American investment that helps China develop weapons and investment that helps bring a promising cancer treatment to patients. Rules that fail to distinguish between the two could deprive Americans of new medicines while weakening our domestic pharmaceutical industry." (Source: PRI news email)

"... The proposed rules are not retroactive, and the existing OISP [Outbound Investment Security Program] framework will remain in effect while Treasury completes the rulemaking. The COINS Act requires Treasury to issue final implementing regulations by March 13, 2027. ..."

Washington’s Proposed China Crackdown Could Backfire on American Patients – DC Journal - InsideSources "Several of the most exciting breakthroughs in cancer care are coming from China. New rules proposed by the Trump administration could make it harder for American patients to access those medicines."

No comments: